website statistics

What Is A Royalty Purchase Agreement

By  | 

“Today`s announcement is the first asset acquired by the XOMA team as part of our business model of royalties and milestone aggregators to reach a clinical milestone. We congratulate Merck on its early clinical success with MK-4830 and hope that this positive development will eventually result in a new treatment option for patients with non-small cell lung cancer,” said Jim Neal, Chief Executive Officer at XOMA. This agreement also provides for the responsibilities of the party that uses intellectual property rights. It contains all the conditions relating to the use of intellectual property. Another feature of licensing agreements is that they normally state that if the owner dies, the royalties are transferred to an heir who is mentioned in the agreement. Use the form below to download a license agreement from the RoyaltyRange database. If you are considering granting your intellectual property or becoming a licensee, you must be familiar with licensing agreements. A company`s licensing agreement is a central element of any licensing agreement and ensures that both parties are properly compensated for their contributions. In this article, we explain what a licensing agreement is and give you an example of when it could be used. At the end of this page, you can download a license agreement so you can see an example of what is included in a license agreement and how it is designed. Safe Harbor Statement Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements about the potential of the XOMA portfolio of licensed partner programs and technologies that , over time, generate an important step and generate added value for shareholders. , cash flow forecasts, economic prospects and the potential effects of the COVID 19 pandemic. These assertions are based on assumptions that may prove to be incorrect and actual results could be significantly exceeded by the expected results, given that some risks exist in the biotechnology industry, including those related to the fact that our products subject to out licensing agreements are still under development, and our licensees may need significant resources to pursue development that may not be available; we do not know whether there will be, or will be, a viable market for products on which we have a right of ownership or license; If applicants for therapeutic products to which we have an interest in royalties do not obtain the approval of the authorities, our third-party licensees will not be able to market them and the impact of the COVID 19 pandemic on the global economy.

Other potential risks for XOMA meeting these expectations are described in more detail in XOMA`s recent submission on Form 10-K and in other SEC submissions. If you consider XOMA`s outlook, consider these risks carefully. Any forward-looking statements in this press release do not present XOMA`s views until the time of this press release and should not be used as a representative of XOMA`s subsequent views. XOMA denies any obligation to update any forward-looking statements, unless required by law. At the time of this press release, all assets are subject to a portfolio of XOMA audit link milestones and licenses.